Clinical trials
Adrenal Cortical Carcinoma clinical trials
Below are recruiting adrenal cortical carcinoma clinical trials, each written for real people, not researchers. We’re tracking 11 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06487481RecruitingPhase 1
Radiation before surgery for recurrent adrenal cancer
This trial tests whether giving radiation before surgery helps people with adrenal cancer that has come back after previous treatment. It aims to see if this approach can improve outcomes for patients who can have surgery at the NIH.
Bethesda, MarylandAges 18–120 - NCT06900595RecruitingPhase 2
Cabozantinib with immunotherapy for advanced adrenal cancer
This trial tests adding the targeted drug cabozantinib to the immunotherapy cemiplimab for people with advanced adrenocortical carcinoma that cannot be removed by surgery or has spread. It checks if the combination works better than cabozantinib alone.
Phoenix, ArizonaAges 12 years+ - NCT05286814RecruitingPhase 2
Pump-delivered therapy plus chemo for liver-metastatic cancers
This phase 2 study tests a liver-targeted medicine delivered through a special implanted pump, combined with standard chemo, for cancers that spread mainly to the liver. It may help control tumor growth in the liver and improve outcomes compared with standard treatment alone.
Bethesda, MarylandAges 18–120 - NCT06006013RecruitingPhase 2
Cabozantinib and pembrolizumab for adrenal cancer
This trial tests a combination of two drugs (cabozantinib and pembrolizumab) for adrenal cancer that has spread or cannot be removed by surgery. It may be an option if you have not had treatment before or have already tried other therapies.
Atlanta, GeorgiaAges 18 years+ - NCT06041516RecruitingPhase 1
New drug ADCT-701 for neuroendocrine and nerve tumors
This trial tests a new drug called ADCT-701 for people with certain rare cancers (neuroendocrine tumors, adrenal cancer, or a type of nerve tumor) that have come back or spread. The drug is an antibody-drug conjugate, which works like a targeted missile to kill cancer cells while trying to spare healthy ones.
Bethesda, MarylandAges 18–120 - NCT06587802RecruitingPhase 2
PD-1 antibody and radiation for advanced adrenal cancer
This trial tests a combination of an immunotherapy drug (PD-1 antibody) and radiation therapy for people with adrenal cortical carcinoma that has come back or spread and can't be removed with surgery. The goal is to see if this combination can help shrink or control the cancer when other treatments have stopped working.
Guangzhou, GuangdongAges 18 years+ - NCT06831175RecruitingPhase 2
PD-1 inhibitor combined with apatinib and mitotane for advanced adrenal cancer
This trial tests a new combination of drugs (PD-1 inhibitor, apatinib, and mitotane) for people with advanced adrenal cortical carcinoma that cannot be removed by surgery. The goal is to see if this combination is safe and effective for those who have not yet received standard first-line treatment.
Chengdu, SichuanAges 18–70 - NCT07335679Recruiting
Strasbourg adrenal cancer patient study
This study looks at patients with adrenal cortex carcinoma who were treated at Strasbourg University Hospital. It aims to better understand the condition and its outcomes.
StrasbourgAges 18 years+ - NCT06141369Recruiting
Personalized mRNA vaccine for advanced endocrine tumors
This trial tests a personalized mRNA vaccine made from your tumor's genetic information. It is for people with advanced endocrine tumors who have no standard treatment options left, and aims to help the immune system fight the cancer.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06683846RecruitingPhase 2
Ivonescimab for advanced rare tumors: a safety & early-efficacy study
This trial tests a drug called ivonescimab in people with advanced, rare tumor types that have spread (stage IV). The goal is to see if the drug is safe and whether it can shrink tumors or slow their growth.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT07085572RecruitingPhase 2
Cemiplimab for maintenance in adrenocortical cancer
This trial tests a drug called cemiplimab as a maintenance treatment for patients with adrenocortical cancer whose disease did not worsen after initial chemotherapy. It is designed to keep the cancer from coming back.
Brescia, BresciaAges 18 years+
Hear when a new Adrenal Cortical Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for adrenal cortical carcinoma?
- Yes. Clin2 currently lists 11 recruiting adrenal cortical carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a adrenal cortical carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a adrenal cortical carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.